Literature DB >> 27062706

Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma.

Zehra Dilek Kanmaz1, Gülfidan Aras1, Esin Tuncay1, Ayşe Bahadır1, Celalettin Kocatürk1, Zehra Asuk Yaşar2, Büge Öz3, Canan Ünlü Özkurt3, Cihan Gündoğan4, Tevfik Fikret Çermik4.   

Abstract

AIM: The aim of this study is to evaluate the diagnostic value of PET-CT scan for the prediction of EGFR mutation status and the contribution of TTF-1 expression to PET-CT scan.
METHODS: We retrospectively studied 218 cases with a diagnosis of pulmonary adenocarcinoma between 2012-2014 which underwent EGFR analysis, TTF-1 and PET-CT before treatment.
RESULTS: The EGFR mutation was present in 28.9% (n= 63) of cases. TTF-1 positivity was 66.9% (n= 105). Standardized uptake value (SUV max) was 16.7 ± 6.8 in EGFR mutant type, 13.8 ± 7.6 in cases having no EGFR mutations. According to our evaluations, high SUVmax is positively correlated with EGFR mutation status. TTF-1 expression in multivariate analysis strengthens the accuracy of detecting an EGFR mutation.
CONCLUSION: PET-CT FDG uptake may, together with TTF-1 expression, help diagnosis in lung adenocarcinoma cases when evaluating for EGFR mutation status.

Entities:  

Keywords:  EGFR; Lung cancer; TTF-1

Mesh:

Substances:

Year:  2016        PMID: 27062706     DOI: 10.3233/CBM-160588

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  7 in total

1.  Predictive value of intratumor metabolic and heterogeneity parameters on [18F]FDG PET/CT for EGFR mutations in patients with lung adenocarcinoma.

Authors:  Ming Ni; Shicun Wang; Xin Liu; Qin Shi; Xingxing Zhu; Yifan Zhang; Qiang Xie; Weifu Lv
Journal:  Jpn J Radiol       Date:  2022-10-11       Impact factor: 2.701

2.  PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs.

Authors:  Liping Yang; Panpan Xu; Mengyue Li; Menglu Wang; Mengye Peng; Ying Zhang; Tingting Wu; Wenjie Chu; Kezheng Wang; Hongxue Meng; Lingbo Zhang
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

3.  Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.

Authors:  Zhilei Lv; Jinshuo Fan; Juanjuan Xu; Feng Wu; Qi Huang; Mengfei Guo; Tingting Liao; Shuqing Liu; Xiaoli Lan; Shanshan Liao; Wei Geng; Yang Jin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-21       Impact factor: 9.236

4.  Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma.

Authors:  Zhencong Chen; Ming Li; Ke Ma; Guoguo Shang; Jiaqi Liang; Jiacheng Yin; Jizhuang Luo; Cheng Zhan; Yu Shi; Qun Wang
Journal:  Cancer Med       Date:  2019-11-25       Impact factor: 4.452

5.  Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients.

Authors:  Yubo Wang; Rui Han; Qiushi Wang; Jie Zheng; Caiyu Lin; Conghua Lu; Li Li; Hengyi Chen; Rongbing Jin; Yong He
Journal:  Int J Gen Med       Date:  2021-02-03

6.  Combination of 18F-Fluorodeoxyglucose PET/CT Radiomics and Clinical Features for Predicting Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.

Authors:  Shen Li; Yadi Li; Min Zhao; Pengyuan Wang; Jun Xin
Journal:  Korean J Radiol       Date:  2022-09       Impact factor: 7.109

7.  Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center.

Authors:  Malahat Musayeva; Serpil Dizbay Sak; Hilal Özakıncı; Şenay Boyacıgil; Öznur Coşkun
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-01-23       Impact factor: 0.332

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.